DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ILEVRO

Summary for Tradename: ILEVRO

Patents:3
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 ILEVRO

Pharmacology for Tradename: ILEVRO

Clinical Trials for: ILEVRO

Nepafenac 0.3% Two Study
Status: Completed Condition: Cataract

Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema
Status: Active, not recruiting Condition: Diabetic Macular Edema

Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation
Status: Recruiting Condition: Macular Thickening; Macular Edema

Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes
Status: Completed Condition: Intraocular Pressure

Confirmatory Study Nepafenac 0.3%
Status: Completed Condition: Cataract

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Status: Completed Condition: Inflammation; Pseudophakia

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Status: Recruiting Condition: Cataract; Retinal Edema; Inflammation

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
Status: Completed Condition: Macular Edema

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
Status: Completed Condition: Cataracts

Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)
Status: Completed Condition: Intraocular Pressure

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Res Ltd
ILEVRO
nepafenac
SUSPENSION/DROPS;OPHTHALMIC203491Oct 16, 2012RXYes<disabled><disabled>
Alcon Res Ltd
ILEVRO
nepafenac
SUSPENSION/DROPS;OPHTHALMIC203491Oct 16, 2012RXYes5,475,034<disabled><disabled>
Alcon Res Ltd
ILEVRO
nepafenac
SUSPENSION/DROPS;OPHTHALMIC203491Oct 16, 2012RXYes6,403,609<disabled>Y<disabled>
Alcon Res Ltd
ILEVRO
nepafenac
SUSPENSION/DROPS;OPHTHALMIC203491Oct 16, 2012RXYes7,947,295<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc